Alfacell Begin Comparison Phase III With Onconase And Lilly's Gemzar
- Alfacell has begun a new Phase III trial comparing its novel RNase product Onconase in combination with tamoxifen to Eli Lilly's Gemzar (gemcitabine) in patients with advanced pancreatic cancer, one of the most difficult tumors to treat. The new trial will be used in addition to an ongoing Phase III study to support a marketing application for Onconase in the USA and elsewhere. Gemzar was approved earlier this year in the USA and became the first new drug for pancreatic cancer in decades (Marketletter May 27). Meantime, the company has reported that Onconase inhibits HIV replication in several persistently-infected human cell lines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze